newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

  • SELLAS Life Sciences Group, Inc. priced its underwritten public offering of 11,538,462 common shares at $13.00 per share.
  • The offering involves the sale of all shares by SELLAS, with expected gross proceeds of $150.0 million before deducting underwriting discounts, commissions, & offering expenses.
  • Underwriters have a 30-day option to purchase up to 1,730,769 additional shares at the public offering price.
  • The offering is expected to close on November 20, 2026, subject to customary closing conditions.
  • J.P. Morgan & TD Cowen serve as lead book-running managers, while Mizuho acts as a book-running manager.
  • A.G.P./Alliance Global Partners & Maxim Group LLC act as lead managers for the offering.
  • The offering is made pursuant to a Form S-3 shelf registration statement filed with the SEC on March 20, 2026.
  • SELLAS develops GPS, a WT1-targeting therapeutic licensed from Memorial Sloan Kettering Cancer Center, & SLS009 (tambiciclib), a CDK9 inhibitor for AML treatment.
Company
SELLAS Life Sciences Group, Inc.
Keywords
Nasdaq:SLS, SELLAS Life Sciences Group, Inc.